Navigation Links
Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007
Date:11/6/2007

>

and Texas -- markets initially targeted for the first series of plants.

These activities included identifying and securing control of unique

sites, arranging for the planting of "test" plantations of dedicated

energy crops and initiating the negotiation of long-term feedstock

contracts.

Specialty Enzymes Business Unit

The Specialty Enzymes Business Unit made solid progress during the third quarter, accelerating its transition into a business focused on the development and commercialization of its own products. Importantly, for example, the Company began selling its Fuelzyme-LF alpha-amylase enzyme to the grain ethanol industry through its own direct sales force earlier this year and has already achieved more than $1 million in sales through the third quarter.

In order to support the development of a growth-oriented commercial business, several important new initiatives have also been implemented that include a reorganization of the Company's sales and marketing team around dedicated product managers responsible for driving sustainable and profitable sales growth of our most promising enzyme products. Additionally, the Company continues to undergo a portfolio review process to focus resources on those products with the greatest commercial opportunity.

"We remain committed to leveraging the scientific depth and breadth inherent in our enzyme business to build a growth-oriented commercial business that is strategically aligned with the long-term goals of the Company," added Mr. Riva. "Through our ongoing portfolio review process, we expect to identify the most appropriate opportunities for future development as we consider the continued growth and success of our business."

Additional Specialty Enzymes Business Unit highlights for the third quarter include:

-- In September, the Company announced that it had achieved a key

technical milestone in its collaboration with Cargill on a new
'/>"/>

SOURCE Verenium Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... A US Airman, fresh from basic training...leukemia patient whose life he saved by donating h...san Air Base, Republic of Korea (PRWEB) November 2...Airman whose blood donation saved her life, met fo...Nov. 21, 2008. , , , , ,Airman Tamarias Pope, 8th...
(Date:11/21/2008)...g of shareholders to be held on January 8, 2009 ,... Med-Emerg International Inc. ("MedEmerg") (OTCBB:...h services, announced today that it has obtained a... Justice concerning its previously announced plan ...ch AIM Health Group Inc. ("AIM") will acquire all ...
(Date:11/21/2008)...., Nov. 21 Heska Corpora...esent at the New York Society of,Security Analyst...ence on,December 2, 2008 at 1177 Avenue of the Am...on is scheduled to begin at 9:35 a.m. Eastern Time...via live webcast and for two weeks,following the ...
(Date:11/21/2008)...Banzel proved effective against Lennox-Gastaut syn...s) -- A new drug called Banzel (rufinamide) has be...ere form of epilepsy called Lennox-Gastaut syndrom... Friday. , The approval was based on results of...s ages 4 to 30. Compared to patients who took a pl...
Breaking Medicine News(10 mins):Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...study shows a clear link between fast food consump...sting that // fast food increases the risk of obes...the association between reported fast food habits ...insulin resistance over 15 years. The diets of mor...
...nk between migraines and the risk of coronary hear...t study shows // no link between the two but does ...est pain, also known as angina. People with a hist... aura -- seeing what appears to be spots or lines ...
...t form of macular degeneration represents about 10...lated macular degeneration is the leading cause of...rs of age and older. // Two new studies show a the...n effective treatment for age-related, "wet" macul...
..., more intense physical activity can help maintain...rchers according to // a new study. For the study ...1900 and 1920 from the Finland, Italy, and Netherl...ty of physical activities of the participants was ...
Other Medicine News:
(Date:11/20/2008).... 20 PAREXEL Internation... biopharmaceutical services provider, today announ...provide regulatory consulting and clinical researc...ce, PAREXEL now has locations throughout five impo...which also include Argentina, Brazil, Chile, and M...
(Date:11/19/2008)...ientists report basic findings on critical enzyme,...better treat an array of disorders , , MEMP...ientists at St. Jude Children,s Research Hospital ... the body,s enzyme workhorses called calpains. ,...lpains function in many cellular processes, includ...
(Date:11/18/2008)...christmasseals.org to learn more, make a donation...NGTON, Nov. 17 Millions...th, courtesy of the American Lung Association. The... fundraising tradition dating back to 1907 when th...osis. , , "Most Americans alive today hav...
(Date:11/13/2008)..., Mass., Nov. 13 Hologic...facturer and supplier of premium,diagnostics, medi...d to,serving the healthcare needs of women, today ...k pivotal clinical trial. The Cervista HPV high-ri...e U.S. and is expected to be,launched in the Europ...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4PhoneTree Announces New Patient Messaging Product and Pricing Options 4660 1Roper Industries Announces Record Third Quarter Results 4657 1Roper Industries Announces Record Third Quarter Results 4657 2Roper Industries Announces Record Third Quarter Results 4657 3Roper Industries Announces Record Third Quarter Results 4657 4Roper Industries Announces Record Third Quarter Results 4657 5Roper Industries Announces Record Third Quarter Results 4657 6Roper Industries Announces Record Third Quarter Results 4657 7Roper Industries Announces Record Third Quarter Results 4657 8Roper Industries Announces Record Third Quarter Results 4657 9Roper Industries Announces Record Third Quarter Results 4657 10Male Drivers are Hitting Killing Most Child Pedestrians New Study Shows 4654 1Male Drivers are Hitting Killing Most Child Pedestrians New Study Shows 4654 2Male Drivers are Hitting Killing Most Child Pedestrians New Study Shows 4654 3California Association of Marriage 26 Family Therapists Offers Tips on How to Cope With a Traumatic Event 4651 1California Association of Marriage 26 Family Therapists Offers Tips on How to Cope With a Traumatic Event 4651 2
... at International Conference on Antiviral,Research...- ADVENTRX,Pharmaceuticals, Inc. , a biopharmaceut...ommercializing proprietary product,candidates for ...nnounced today that it presented results demonstra...influenza (bird flu) viruses when,the Company,s br...
...Plus Minocycline Showed Substantial,Reduction of D...Remitting Multiple Sclerosis , Combination Treatme...nd Was Well Tolerated , KANSAS CITY, Mo, May 4, 20...y showed that a combination of Copaxone,(glatirame...c,minocycline reduced T1 Gadolinium (Gd)-enhancing...
Other Medicine Technology:ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 2ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12
Needle holder, delicate, curved without lock
Rhoton microscopic forceps, straight
Microscopic scissors, curved
Our unique velcro design apron with elasticized back panels for additional support and comfort. Shoulder pads are a standard. Shoulder drop-away optional.
Medicine Products: